For complete content of abstracts prior to 2022, please go to the past annual meeting pages (Annual Meeting menu on top of this page).

CMSC Abstracts Search Form (Titles and Authors only)

Search Accepted Abstracts
Sending

Search Results

Year ID Type Category Title Authors
2022 DMT01 Platform/Oral Disease Modifying Therapies

Treatment-Emergent COVID-19 in Ozanimod Multiple Sclerosis and Ulcerative Colitis Clinical Trials

Bruce A.C. Cree, MD, PhD1, Ryan C. Ungaro, MD2, Jean-Frederic Colombel, MD2, Corey A. Siegel, MD, MS3, James K. Sheffield, MD4, John Vaile, PharmD4, Harris A. Ahmad, MD4, Ashwini Pai, MD4, Shabana Ather, MD4, Lorna Charles, MD4, AnnKatrin Petersen, MD4, Chun-Yen Cheng, PhD4, Sonia Afsari, MD4 and Krzysztof W. Selmaj, MD5, (1)Neurology, Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA, (2)Icahn School of Medicine at Mount Sinai, New York, NY, (3)Dartmouth-Hitchcock Medical Center, Lebanon, NH, (4)Bristol Myers Squibb, Princeton, NJ, (5)Center for Neurology, ?ód?, Poland, and Department of Neurology, University of Warmia & Mazury, Olsztyn, Poland

2022 DMT02 Platform/Oral Disease Modifying Therapies

Safety and Efficacy of Evobrutinib, a Bruton’s Tyrosine Kinase Inhibitor, in Relapsing Multiple Sclerosis over 2.5 Years of the Open-Label Extension to a Phase II Trial

Xavier Montalban, MD PhD1, Jerry S Wolinsky, MD2, Douglas L Arnold, MD3,4, Martin S Weber, MD5, Ivan Staikov, MD PhD6, Karolina Piasecka-Stryczynska, PhD7, Davorka Tomic, PhD8, Emily C Martin, PhD9, Kristina H Holmberg, PhD9 and Hans Guehring, MD10, (1)Department of Neurology-Neuroimmunology, Centre d’Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitario Vall d’Hebron, Barcelona, Spain, (2)McGovern Medical School, The University of Texas Health Science Center at Houston (UTHealth), Houston, TX, (3)Montreal Neurological Institute, McGill University, Montréal, QC, Canada, (4)NeuroRx Research, Montréal, QC, Canada, (5)Institute of Neuropathology and Department of Neurology, University Medical Center, University of Göttingen, Göttingen, Germany, (6)Department of Neurology, Acibadem City Clinic Tokuda Hospital, Sofia, Bulgaria, (7)Department of Neurology and Cerebrovascular Diseases, Pozna? University of Medical Sciences, Pozna?, Poland, (8)Ares Trading SA, an affiliate of Merck KGaA, Darmstadt, Germany, Eysins, Switzerland, (9)EMD Serono, Billerica, MA, (10)The healthcare business of Merck KGaA, Darmstadt, Germany

2022 DMT03 Platform/Oral Disease Modifying Therapies

Reduced Disease Progression with Ublituximab Vs Teriflunomide in the Phase 3 Ultimate I and II Studies in Relapsing Multiple Sclerosis

Enrique Alvarez, MD, PhD, University of Colorado, Aurora, CO, Lawrence Steinman, MD, Beckman Center for Molecular Medicine, Stanford University Medical Center, Stanford, CA, Edward J Fox, MD, PhD, Central Texas Neurology Consultants, Multiple Sclerosis Clinic of Central Texas, Round Rock, TX, Hans-Peter Hartung, MD, Heinrich Heine University, Dusseldorf, Germany; Brain and Mind Centre, University of Sydney, Sydney, Australia; Department of Neurology, Medical University of Vienna, Vienna, Austria; Department of Neurology, Palacky University, Olomouc, Czech Republic, Peiqing Qian, MD, Swedish Medical Center, Seattle, WA, Sibyl Wray, MD, Hope Neurology, Knoxville, TN, Derrick Robertson, MD, University of South Florida, Tampa, FL, DeRen Huang, MD, PhD, Center for Multiple Sclerosis, Mount Carmel Health System, Westerville, OH, Krysztof Selmaj, MD, PhD, Center of Neurology, Lodz, Poland; Department of Neurology, University of Warmia & Mazury, Olsztyn, Poland, Daniel Wynn, MD, Consultants in Neurology MS Center, Northbrook, IL, Lily Lee, PhD, TG Therapeutics, New York, NY and Bruce A Cree, MD, PhD, MAS, UCSF Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, CA

2022 DMT04 Platform/Oral Disease Modifying Therapies

Longer-Term Safety of Ofatumumab in Patients with Relapsing Multiple Sclerosis

Jacqueline A Nicholas, MD, MPH1, Stephen L Hauser, PhD2, Anne H Cross, MD3, Kevin Winthrop, MD, MPH4, Heinz Wiendl, MD, MPH5, Sven G Meuth, MD, PhD6, Paul S Giacomini, MD7, Francesco Sacca, MD8, Ronald Zielman, MD, PhD9, Xixi Hu, PhD10, Ayan Das Gupta, Msc11, Roseanne Sullivan, PharmD10, Virginia DeLas Heras, MD12, Wendy Su, PhD10 and Ludwig Kappos, MD13, (1)OhioHealth Multiple Sclerosis Center, Columbus, OH, (2)UCSF Weill Institute for Neurosciences, University of California, San Francisco, CA, (3)Washington University School of Medicine, Saint Louis, MO, (4)Public Health and Preventive Medicine, Division of Infectious Diseases, Oregon Health and Sciences University, Portland, OR, (5)University of Muenster, Muenster, Germany, (6)Department of Neurology, Medical Faculty, Heinrich-Heine-University, Düsseldorf, Germany, (7)Department of Neurology and Neurosurgery, Montreal Neurological Institute, McGill University, Montreal, QC, Canada, (8)NSRO Department, University “Federico II” of Naples, Naples, Italy, (9)Novartis Pharma B.V., Amsterdam, Netherlands, (10)Novartis Pharmaceuticals Corporation, East Hanover, NJ, (11)Novartis Healthcare Pvt. Ltd, Hyderabad, India, (12)Novartis Pharma AG, Basel, Switzerland, (13)Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB) and MS Center, Departments of Head, Spine and Neuromedicine, Clinical Research, Biomedicine and Biomedical Engineering, University Hospital and University of Basel, Basel, Switzerland

2022 DMT05 Platform/Oral Disease Modifying Therapies

Benefits of Repeated Confirmed Disability Progressions Analyses in MS Clinical Trials: A Case Study Using the Opera and Oratorio Trials and Their Open-Label Extensions

Jerry S Wolinsky, MD1, Hans-Peter Hartung, MD2,3, Stephen L. Hauser, MD4, Robert T. Naismith, MD5, Hans-Martin Schneble, MD6, Ben Townsend, PhD6, Qing Wang, PhD6 and Ludwig Kappos, PhD7, (1)McGovern Medical School, The University of Texas Health Science Center at Houston (UTHealth), Houston, TX, (2)Department of Neurology, UKD, Center of Neurology and Neuropsychiatry and LVR-Klinikum, Heinrich Heine University Düsseldorf, Düsseldorf, Germany, (3)Brain and Mind Centre, University of Sydney, Sydney, Australia, (4)UCSF Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA, (5)Washington University School of Medicine, St. Louis, MO, (6)F. Hoffmann-La Roche Ltd, Basel, Switzerland, (7)Research Center for Clinical Neuroimmunology and Neuroscience, University Hospital Basel, University of Basel, Basel, Switzerland

2022 DMT06 Platform/Oral Disease Modifying Therapies

Perceptions and Discussions on the Use of Disease-Modifying Therapies during Family Planning in Women with Multiple Sclerosis

Riley Bove, MD1, Noemi Pasquarelli, MSc, PhD2, Marina Gafarova, MD, PhD3, Christine Eighteen, MBA2, Natalie Joschko, PhD4, Corey Mandel, PhD5 and Ruth Dobson, PhD, FRCP6, (1)Department of Neurology, Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA, (2)F. Hoffmann-La Roche Ltd, Basel, Switzerland, (3)Roche Moscow JSC, Moscow, Russian Federation, (4)Roche Pharma AG, Grenzach-Wyhlen, Germany, (5)Genentech, Inc., San Francisco, CA, (6)Preventative Neurology Unit, Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, United Kingdom

2022 DXM01 Platform/Oral Disease Management I

A Novel Educational Program for Relationship-Centered Shared Decision Making in Multiple Sclerosis, with a Focus on Cognition

Annette F Okai, MD1, Mitzi J Williams, MD2, Megan Weigel, DNP3, Dana Jones, NP4, Steve Cole, MD5, Richard Frankel, PhD6, Amanda Montague, EdM7, Barry Hendin, MD8, Jennifer Reardon, MD9, Shawn Keogan, MD9, Jean-Pierre Morello, MD9 and Leorah Freeman, MD, PhD10, (1)North Texas Institute of Neurology & Headache, Plano, TX, (2)Joi Life Wellness, MS Neurology Center, Smyrna, GA, (3)First Coast Integrative Medicine, Jacksonville, FL, (4)Holy Name Medical Center, Teaneck, NJ, (5)Stony Brook University School of Medicine, Stony Brook, NY, (6)Indiana University of Medicine, Indianapolis, IN, (7)Multiple Sclerosis Association of America, Cherry Hill, NJ, (8)Center for Neurology and Spine, Phoenix, AZ, (9)Bristol Myers Squibb, Princeton, NJ, (10)Neurology, Dell Medical School, The University of Texas at Austin, Austin, TX

2022 DXM02 Platform/Oral Disease Management I

Recognition and Awareness of Spasticity in Multiple Sclerosis – Optimizing the Patient/Clinical Dialogue – SEEN-MSS Survey

Barry Hendin, MD1, Ben W Thrower, MD2, Scott D. Newsome, DO, MSCS, FAAN, FANA3, Robert Chinnapongse, MD4, Sherry Danese, BS, MBA5 and Jenifer Patterson, ARNP, MSCN4, (1)Center for Neurology and Spine, Phoenix, AZ, (2)Crawford Research Institute, Shepherd Center, Atlanta, GA, (3)Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, (4)Jazz Pharmaceuticals, Carlsbad, CA, (5)Outcomes Insights, Agoura Hills, CA

2022 DXM03 Platform/Oral Disease Management I

Enrollment of Non-White Participants and Reporting of Race and Ethnicity in Phase III Trials of MS Dmts: A Systematic Review

Helen-Margaret O Onuorah, BA1, Odelin Charron, MSc, MSE1, Ethan Meltzer, MD1, Amanda Montague, EdM2, Alexis Crispino, BA2, Avery Largent, BA1, Ashlea Lucas, PA-C1 and Leorah Freeman, MD, PhD1, (1)Neurology, Dell Medical School, The University of Texas at Austin, Austin, TX, (2)Multiple Sclerosis Association of America, Cherry Hill, NJ

2022 DXM04 Platform/Oral Disease Management I

Spinal Movement Disorders in Transverse Myelitis, Nmosd, and Mogad

Hesham Abboud, MD, PhD, Case Western Reserve School of Medicine – – Cleveland Heights, OH, Cleveland, OH; Multiple Sclerosis and Neuroimmunology Program, University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, OH, Rongyi Sun, BS, Case Western Reserve University School of Medicine, Cleveland, OH and Nikhil Modak, MD, University Hospitals of Cleveland, Cleveland, OH

2022 DXM05 Platform/Oral Disease Management I

Demographics and Baseline Disease Characteristics of Black and Hispanic Patients with Multiple Sclerosis in the Chimes Trial

Lilyana Amezcua, MD1, Annette F Okai, MD2, Anne H Cross, MD3, Nancy L Monson, PhD4, Ben W Thrower, MD5, Anthony T Reder, MD6, Jeffrey B English, MD7, Gregory F Wu, MD, PhD3, Evanthia Bernitsas, MD8, Shereen Yap, MSc9, Jugena Ndrio, PharmD9, Jinglan Pei, PhD9, Ellen M Mowry, MD, MCR10, Fabio Magrini, MD9 and Mitzi J Williams, MD11, (1)Keck School of Medicine, University of Southern California, Los Angeles, CA, (2)North Texas Institute of Neurology & Headache, Plano, TX, (3)Washington University School of Medicine, St. Louis, MO, (4)University of Texas Southwestern Medical Center, Dallas, TX, (5)Crawford Research Institute, Shepherd Center, Atlanta, GA, (6)University of Chicago Medicine, Chicago, IL, (7)Multiple Sclerosis Center of Atlanta, Atlanta, GA, (8)Wayne State University School of Medicine, Detroit, MI, (9)Genentech, Inc., South San Francisco, CA, (10)Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, (11)Joi Life Wellness Group MS Center, Smyrna, GA

2022 DXM06 Platform/Oral Disease Management I

The Relationship of Aspects of the Shared Decision Making Process and Vaccination Hesitancy in People with Multiple Sclerosis

Olivia Kaczmarek, BS1, Ellie Teng, BS2, Avtej Sethi, MS2, Barbara Bumstead, MS, ANCP, MSCN2, Marijean Buhse, NP-C, PhD2, Myassar Zarif, MD2 and Mark Gudesblatt, MD3, (1)South Shore Neurologic Associates, Patchogue, NY, (2)South Shore Neurologic Associates, P.C., Patchogue, NY, (3)South Shore Neurologic Associates, P.C., Islip, NY

2022 DXM07 Platform/Oral Disease Management II

Characterizing Prospective Memory Errors and Their Neuropsychological Correlations in Persons with MS

Caitlyn Nguyen, HS1, Sarah A Raskin, PhD2,3, Aaron P Turner, Ph.D. ABPP (RP)4,5,6, Zaenab Dhari, MD7,8, Lindsay O Neto, MPH7,8 and Elizabeth S Gromisch, PhD, MSCS8,9,10, (1)Trinity College, Hartford, CT, (2)Neuroscience Program, Trinity College, Hartford, CT, (3)Department of Psychology, Trinity College, Hartford, CT, (4)Department of Rehabilitation Medicine, University of Washington, Seattle, WA, (5)Rehabilitation Care Service, VA Puget Sound Health Care System, Seattle, WA, (6)Multiple Sclerosis Center of Excellence West, Veterans Affairs, Seattle, WA, (7)Department of Rehabilitative Medicine, Frank H. Netter MD School of Medicine at Quinnipiac University, North Haven, CT, (8)Mandell Center for Multiple Sclerosis, Mount Sinai Rehabilitation Hospital, Trinity Health Of New England, Hartford, CT, (9)Department of Neurology, University of Connecticut School of Medicine, Farmington, CT, (10)Departments of Rehabilitative Medicine and Medical Sciences, Frank H. Netter MD School of Medicine at Quinnipiac University, North Haven, CT

2022 DXM08 Platform/Oral Disease Management II

Comparative Diagnostic and Therapeutic Strategies Among General and Multiple Sclerosis (MS) Subspecialist Neurologists – Opportunities for Education

Andrew J Solomon, MD1, Jiwon Oh, MD PhD FRCPC2, Robert A Bermel, MD3, Adnan Subei, DO4, Chloe Gianatasio, MS5, Natalie Goldberg, PhD5, Wendy Cerenzia, MS6 and Brian Moss, MBA5, (1)Neurological Sciences, University of Vermont College of Medicine, Burlington, VT, (2)Medicine, Division of Neurology, St. Michael’s Hospital, Univ of Toronto, Toronto, ON, Canada, (3)Mellen Center for MS, Cleveland Clinic, Cleveland, OH, (4)Neurology, Memorial Healthcare System, Hollywood, FL, (5)Efficient CME, Fort Lauderdale, FL, (6)CE Outcomes, LLC, Birmingham, AL

2022 DXM09 Platform/Oral Disease Management II

COVID-19 Vaccination Intent and Uptake in People with MS: A Longitudinal Survey Study

Odelin Charron, MSc, MSE1, Kenneth Onuorah, AS Candidate1, Helen-Margaret O Onuorah, BA1, Amanda Montague, EdM2, Alexis Crispino, BA2, Randa Hamden, PhD, MPH3, Trudy Krause, DrPH, MS3, Avery Largent, BA1, Ashlea Lucas, PA-C1, Ethan Meltzer, MD1 and Leorah Freeman, MD, PhD1, (1)Neurology, Dell Medical School, The University of Texas at Austin, Austin, TX, (2)Multiple Sclerosis Association of America, Cherry Hill, NJ, (3)Center for Healthcare Data, School of Public Health, The University of Texas Health Science Center at Houston, Houston, TX

2022 DXM10 Platform/Oral Disease Management II

Predicting Satisfaction with Functioning in Psychosocial Life Areas for People with MS

Louise C Palmer, MA1, Mark Sweatman, PhD2, James Krause, Ph.D.3, Melinda Jarnecke, BS4 and Deborah Backus, PT, PhD1, (1)Shepherd Center, Atlanta, GA, (2)Georgia Gwinnett College, Lawrenceville, GA, (3)Professor and Associate Dean for Research, Medical University of South Carolina, Columbia, SC, (4)Medical University of South Carolina, Charleston, SC

2022 DXM11 Platform/Oral Disease Management II

Improving Measures of Atrophy, Black Holes and Lesions and Their Impact on Diagnosis and Care.

Marek Podyma, PhD, Pixel Technology, Lodz, Poland and Malgorzata Siger, MD PhD, Neurology, Medical University of Lodz, Lodz, Poland

2022 DXM12 Platform/Oral Disease Management II

Effects on Quality of Life, Disease Impact and Physical Activity of a Day Wellness Program for People Living with Multiple Sclerosis before and during the COVID-19 Pandemic.

Tiffany Malone, MSW, MSCS1, John Schafer, MD2, Lacey Sayre, CNA1 and Brian Hutchinson, PT, MSCS3, (1)Multiple Sclerosis Achievement Center, Dignity Health, Citrus Heights, CA, (2)Multiple Sclerosis Achievement Center, Citrus Heights, CA, (3)Multiple Sclerosis Achievement Center, Dignity Health, Sacramento, CA

2022 REH01 Platform/Oral Rehabilitation

Impact of Functional Electrical Stimulation Cycling on Performance Measures in People with Secondary Progressive Multiple Sclerosis

Alexandra C Simpson, MD, MA1, Sandra D. Cassard, ScD2, Michael Comisac, n/a3, Danielle Obando, n/a3, Kathleen M Zackowski, PhD, OT4, Daniel Becker, MD5, Jennifer Keller, MSPT6 and Scott D. Newsome, DO, MSCS, FAAN, FANA1, (1)Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, (2)Neurology, Johns Hopkins School of Medicine, Baltimore, MD, (3)Johns Hopkins University School of Medicine, Baltimore, MD, (4)National Multiple Sclerosis Society, New York, NY, (5)International Neurorehabilitation Institute, Lutherville-Timonium, MD, (6)Kennedy Krieger Institute, Baltimore, MD

2022 REH02 Platform/Oral Rehabilitation

Feasibility, Safety, and Patient and Provider Perceptions of a Telewellness Program in MS during COVID-19

Emily Gard, SPT1, Charlotte Rutherford, PT, DPT2, Jared Labrum, PTA1, Bet Hawley, PTA1, James Davis, SPT1 and Hina Garg, PT, MS, PhD, NCS1, (1)Rocky Mountain University of Health Professions, Provo, UT, (2)Boston, MA